Klin Onkol 1995; 8(5): 148-152.
Summary: Vinorelbine is a new semisynthetic cytostatic drug derived from Vinca rosea alcaloids. It differs from the former preparationes by the lower neurotoxicity which enables to use higher doses of vinorelbine to reach stronger antitumor effects. In clinical practice vinorelbine has been used in non-small cell lung and breast cancer patients.
This article comes with basic information on vinorelbine and gives a review of clinical experiences regarding Navelbine in monotherapy and combined chemotherapy for nonresecable lung cancer. A combination of vinorelbine and cisplatin appears to be the best in this indication. It reaches 30 per cent response rate. Above mentioned chemotherapy temporarily improves a quality of life but may prolong survival only by weeks.
